格隆汇8月8日丨复星医药(02196.HK)公告，谨定于2025年8月26日(星期二)举行董事会会议，藉以(其中 包括)考虑及通过公司及其附属公司截至2025年6月30日止6个月的中期业绩并予以刊发。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. * （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 董事會會議日期 上海復星醫藥（ 集團 ）股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於2025年8月 26日（ 星期二 ）舉行董事會會議，藉以（ 其中包括 ）考慮及通過本公司及其附屬公司截至2025 年6月30日止六個月的中期業績並予以刊發。 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董 事 為 陳 啟 宇 先 生 、 潘 東 輝 先 生 及 吳 以 芳 先 生 ； 本 公 司 之 獨 立 非 執 行 董 事 為 余 梓 山 先 生 、 王 全 弟 先 生 、 Chen Penghui先生及楊玉成先生；以及本公 ...

Core Viewpoint - The launch of China's first pharmaceutical ETF fund aims to provide investors with exposure to leading companies in the chemical, biological, and traditional Chinese medicine sectors, capitalizing on the growth potential driven by innovation and demographic trends [1][5]. Industry Overview - The pharmaceutical industry is characterized by its essential nature, driven by a large population, aging demographics, and increasing GDP per capita, which supports long-term growth [5]. - By 2024, the proportion of the population aged 65 and above in China is expected to reach 15.6%, indicating a shift into a moderately aging society, which will further expand the pharmaceutical market [5]. Innovation and Growth - Innovative drugs are seen as a key driver for the pharmaceutical industry's growth, with the potential to unlock new value and re-evaluate medical asset worth [5]. - Domestic innovative drugs are anticipated to experience significant growth in 2024, supported by various internal and external factors, potentially leading to a "Davis Double Play" scenario [5]. - The integration of AI in drug development is expected to accelerate the research and development of new medications [5]. ETF Fund Details - The newly launched ETF fund (A class: 024985 / C class: 024986) will exclusively track the CSI Pharmaceutical Index, which includes leading companies in the chemical, biological, and traditional Chinese medicine sectors [1][19]. - The fund aims to provide a balanced investment approach, combining high-growth innovative drugs with more stable traditional Chinese medicine to mitigate volatility [1][19]. Performance Metrics - The pharmaceutical index has shown a significantly smaller decline compared to similar indices over the past five years, with positive returns over the last three years [14]. - The index's long-term annualized volatility and maximum drawdown are notably lower than those of comparable indices, indicating a more stable investment profile [14]. Key Constituents - The top ten constituents of the pharmaceutical index include major companies such as Heng Rui Medicine (14.91% weight), Pian Zai Ye (5.83%), and Yunnan Baiyao (4.81%), reflecting a diverse representation across the pharmaceutical sectors [13].

数据来源：天眼查APP 证券之星消息，根据天眼查APP数据整理，近日，复星医药产业发展(成都)有限公司成立，法定代表人 为王可心，注册资本1000万元，经营范围包含：一般项目：医学研究和试验发展；药物检测仪器销售； 制药专用设备销售；包装材料及制品销售；普通货物仓储服务(不含危险化学品等需许可审批的项目)； 货物进出口；技术进出口；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；以自有 资金从事投资活动。(除依法须经批准的项目外，凭营业执照依法自主开展经营活动)许可项目：药品委 托生产；药品批发；药物临床试验服务。(依法须经批准的项目，经相关部门批准后方可开展经营活 动，具体经营项目以相关部门批准文件或许可证件为准)。天眼查APP股权穿透显示，该公司由复星医 药全资持股。 ...

Group 1 - The core point of the announcement is that Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the U.S. FDA to conduct Phase I clinical trials for the new drug HLX43, which is a targeted PD-L1 antibody-drug conjugate for the treatment of thymic carcinoma [2][3] - The new drug HLX43 is a conjugate developed by linking a novel DNA topoisomerase I inhibitor with a self-developed PD-L1 targeting antibody, aimed at treating advanced/metastatic solid tumors [3] - As of June 2025, the cumulative R&D investment for this new drug by the group is approximately RMB 182 million (unaudited) [3] Group 2 - There are currently no approved PD-L1 targeted antibody-drug conjugates available in the global market [4]

Core Viewpoint - Fosun Pharma's stock price is currently at 26.37 yuan, reflecting a decline of 0.98% from the previous trading day, with a trading volume of 724 million yuan [1] Company Overview - Fosun Pharma is a large pharmaceutical enterprise focused on drug manufacturing and research, covering the entire pharmaceutical health industry chain [1] - The company's main products include anti-tumor drugs, cardiovascular system drugs, and central nervous system drugs [1] Recent Developments - Fosun Pharma's subsidiary, Fosun Hani, has recently received FDA approval to conduct Phase I clinical trials for HLX43, an injectable drug for the treatment of thymic cancer [1] - HLX43 is a PD-L1 targeted antibody-drug conjugate intended for the treatment of advanced/metastatic solid tumors [1] - The company plans to conduct global multi-center clinical research for this indication in Australia, Japan, and the United States [1] - As of June 2025, the cumulative R&D investment for this new drug is expected to be approximately 182 million yuan [1]

Group 1 - The company announced that its subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., received FDA approval to conduct Phase I clinical trials for HLX43, a PD-L1 targeted antibody-drug conjugate for thymic carcinoma treatment [1] - The company plans to conduct global multi-center clinical research in Australia, Japan, and the United States once conditions are met [1] Group 2 - The pharmaceutical business is the core of the company, focusing on three main areas: innovative drugs, mature products and manufacturing, and vaccines [2] - The innovative drug segment emphasizes oncology and immune-inflammatory treatments, enhancing core technology platforms like antibody/ADC and cell therapy [2] - The mature products and manufacturing segment aims for integrated development, focusing on high-margin products and increasing the proportion of complex generics and modified new drugs [2] - The vaccine business has established a self-developed system centered on bacterial and viral vaccine technology platforms, aiming to accelerate the launch of self-developed vaccine products [2] Group 3 - The company maintains healthy and high-quality development, ranking 4th in the "2023 China Pharmaceutical Industry Top 100 Enterprises" list [3] - It ranked 4th in the comprehensive R&D strength ranking and 3rd in the chemical drug R&D strength ranking in the "2024 China Drug R&D Strength Ranking" [3] - The company was included in the "Global TOP25 Pharmaceutical Companies by Pipeline Size" for the third consecutive year [3] - In 2024, the company's hospital prescription drug sales revenue ranked 12th nationwide according to IQVIA [3] - The company maintained an A rating in the MSCI ESG rating for 2024 and was recognized in various ESG-related rankings [3] Group 4 - For the fiscal year 2024, the company achieved a revenue of 41.067 billion yuan and a net profit of 2.77 billion yuan [4]

Group 1: Company Performance - SMIC reported Q2 revenue of $2.21 billion, a 16% year-over-year increase, but a 1.7% decrease quarter-over-quarter [1] - China Mobile achieved a net profit of 84.2 billion yuan in the first half of 2025, a 5% year-over-year increase, with a mid-term dividend of 2.75 HKD per share, up 5.8% [2] - Huahong Semiconductor's Q2 revenue was $566.1 million, an 18.3% year-over-year increase, with Q3 revenue guidance of $620 million to $640 million [3] Group 2: Business Operations and Developments - Chuangzhong Technology clarified that it does not engage in the production of liquid-cooled servers, only participating in testing platforms, with no revenue generated from this segment in H1 2025 [4] - Shuo Beid announced it has sent samples of liquid-cooled server plates to Taiwanese clients, but the ability to pass testing and achieve mass production remains uncertain [5] - Furi Electronics stated that its subsidiary provides JDM/OEM services for service robots, but this revenue accounts for less than 1% of the company's total revenue [6] Group 3: Industry Trends and Market Movements - Sales of new energy vehicles by Seres reached 44,581 units in July, reflecting a 5.7% year-over-year increase [7] - Longyuan Power completed a power generation of 6,328.76 MWh in July, marking a 2.44% year-over-year growth [8] - Jianglong Shipbuilding won a bid for the "Blue Granary" marine economic development project, indicating ongoing infrastructure investments [8]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., has received FDA approval to initiate Phase I clinical trials for HLX43, a targeted PD-L1 antibody-drug conjugate for thymic carcinoma treatment [1] Group 1: Company Developments - The new drug HLX43 is a conjugate of a novel DNA topoisomerase I inhibitor small molecule toxin-peptide linker and a self-developed PD-L1 targeting antibody [1] - The clinical trials will be conducted globally in locations including Australia, Japan, and the United States once conditions are met [1] Group 2: Industry Context - The targeted PD-L1 antibody-drug conjugate (ADC) is aimed at treating advanced/metastatic solid tumors [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received FDA approval to conduct Phase I clinical trials for HLX43, a targeted PD-L1 antibody-drug conjugate for thymic carcinoma treatment [1] Group 1: FDA Approval and Clinical Trials - The FDA has approved the initiation of Phase I clinical trials for HLX43, a targeted PD-L1 antibody-drug conjugate, for the treatment of thymic carcinoma [1] - Fuhong Hanlin plans to conduct global multi-center clinical research in Australia, Japan, and the United States once conditions are met [1] Group 2: Drug Development and Investment - HLX43 is a conjugate developed by linking a novel DNA topoisomerase I inhibitor small molecule toxin-peptide chain with a self-developed targeted PD-L1 antibody, aimed at treating advanced/metastatic solid tumors [1] - As of June 2025, the cumulative R&D investment for this drug is approximately RMB 182 million (unaudited, single drug) [1] - Currently, there are no approved PD-L1 targeted antibody-drug conjugates available globally [1]